Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998-2001.

This study monitored the serotypes of Streptococcus agalactiae (group B streptococcus; GBS) isolated from invasive infections in western Sweden and investigated possible relationships between serotype, age and clinical manifestations. Invasive GBS isolates were collected prospectively during 1998-2001 at six laboratories, covering two counties with a population of 1.8 million, and were serotyped by coagglutination. Clinical data were obtained from hospital notes. In total, 161 invasive strains (50 from neonates and infants aged < 3 months, and 111 from adults) were serotyped. The commonest serotypes from neonates and infants were serotypes III (60%), V (22%) and Ia (10%), and from adults were serotypes V (42%) and III (25%). Serotype V had doubled in frequency among both children and adults compared to a previous study from the same area in 1988-1997. Most (80%) of the adults had an underlying medical condition. No relationship was found between serotype and clinical manifestations. However, the study demonstrated the importance of active surveillance of GBS serotypes and the difficulties of formulating a multivalent polysaccharide conjugate vaccine against GBS.

[1]  B. Trollfors,et al.  Invasive group B streptococcal infections in Sweden: incidence, predisposing factors and prognosis. , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[2]  B. Trollfors,et al.  Septicaemia and meningitis in neonates and during early infancy in the Göteborg area of Sweden , 2002, Acta paediatrica.

[3]  N. Charland,et al.  Protection from Group B Streptococcal Infection in Neonatal Mice by Maternal Immunization with Recombinant Sip Protein , 2002, Infection and Immunity.

[4]  K. Bergh,et al.  Typing of human isolates of Streptococcus agalactiae (group B streptococcus, GBS) strains from Zimbabwe. , 2002, Journal of medical microbiology.

[5]  D. Kasper,et al.  Conjugate vaccines against group B Streptococcus types IV and VII. , 2002, The Journal of infectious diseases.

[6]  R. Collier,et al.  Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. , 2001, Vaccine.

[7]  J. Troendle,et al.  Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. , 2001, The Journal of infectious diseases.

[8]  H. Davies,et al.  Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. , 2001, The Pediatric infectious disease journal.

[9]  M. Farley Group B streptococcal disease in nonpregnant adults. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  C. Adair,et al.  Antibodies to capsular polysaccharides of group B Streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. , 2001, The Journal of infectious diseases.

[11]  W. Ko,et al.  Serotyping and Antimicrobial Susceptibility of Group B Streptococcus Over an Eight-Year Period in Southern Taiwan , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[12]  L. Paoletti Potency of clinical group B streptococcal conjugate vaccines. , 2001, Vaccine.

[13]  M. Krohn,et al.  Group B Streptococcal Colonization and Serotype‐Specific Immunity in Pregnant Women at Delivery , 2000, Obstetrics and gynecology.

[14]  I. Charlebois,et al.  Identification of Group B Streptococcal Sip Protein, Which Elicits Cross-Protective Immunity , 2000, Infection and Immunity.

[15]  G. Tyrrell,et al.  Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators. , 2000, The Journal of infectious diseases.

[16]  A. Schuchat,et al.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.

[17]  S. Berg,et al.  Serotypes and clinical manifestations of group B streptococcal infections in western Sweden. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  S. Kalliola,et al.  Neonatal group B streptococcal disease in Finland: a ten-year nationwide study. , 1999, The Pediatric infectious disease journal.

[19]  D. Kasper,et al.  Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. , 1999, The Journal of infectious diseases.

[20]  D. Kasper,et al.  Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.

[21]  A. Schuchat Epidemiology of Group B Streptococcal Disease in the United States: Shifting Paradigms , 1998, Clinical Microbiology Reviews.

[22]  A. Schuchat,et al.  Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. , 1998, The Journal of infectious diseases.

[23]  P. Azimi,et al.  Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. , 1997, The Journal of infectious diseases.

[24]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[25]  R. Edelman,et al.  Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. , 1996, Vaccine.

[26]  A. Schuchat,et al.  Invasive group B streptococcal disease: the emergence of serotype V. , 1996, The Journal of infectious diseases.

[27]  L. Bevanger,et al.  A Streptococcus agalactiae R protein analysed by polyclonal and monoclonal antibodies , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[28]  A. Schuchat,et al.  A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. , 1993, The New England journal of medicine.

[29]  G. Lindahl,et al.  Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections , 1993, The Journal of experimental medicine.

[30]  L. Madoff,et al.  Neonatal group B streptococcal infection in Mallorca, Spain. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  L. Burman,et al.  Novel coagglutination method for serotyping group B streptococci , 1992, Journal of clinical microbiology.

[32]  L. Bevanger,et al.  Characterization of the a antigen of the c proteins of group B streptococci (GBS) using a murine monoclonal antibody , 1992, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[33]  A. Schuchat,et al.  Invasive Group B Streptococcal Disease in Adults: A Population-Based Study in Metropolitan Atlanta , 1991 .

[34]  B. Trollfors,et al.  Incidence and Etiology of Neonatal Septicaemia and Meningitis in Western Sweden 1975‐1986 , 1990, Acta paediatrica Scandinavica.

[35]  D. Kasper,et al.  Immunization of Pregnant Women with a Polysaccharide Vaccine of Group B Streptococcus , 1988 .

[36]  J. Motlová,et al.  Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V , 1985, Journal of clinical microbiology.

[37]  M. Klegerman,et al.  Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease , 1984, Infection and immunity.

[38]  D. Kasper,et al.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. , 1977, The Journal of clinical investigation.

[39]  D. Kasper,et al.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. , 1976, The New England journal of medicine.

[40]  R. Krause,et al.  NEW APPROACHES FOR THE LABORATORY RECOGNITION OF M TYPES OF GROUP A STREPTOCOCCI , 1971, The Journal of experimental medicine.

[41]  R. Williams Laboratory diagnosis of streptococcal infections. , 1958, Bulletin of the World Health Organization.

[42]  G. Perlmann,et al.  PREPARATION AND PROPERTIES OF A PROTEIN (R ANTIGEN) OCCURRING IN STREPTOCOCCI OF GROUP A, TYPE 28 AND IN CERTAIN STREPTOCOCCI OF OTHER SEROLOGICAL GROUPS , 1952, The Journal of experimental medicine.